ArticleBMC infectious diseases2026
Serum cryptococcal antigen gradient detection for monitoring the efficacy and medical guidance of the treatment of pulmonary cryptococcosis: a case report.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe duration of drug maintenance therapy for pulmonary cryptococcosis (PC) has been controversial, and good monitoring methods for drug efficacy are lacking. CASE PRESENTATION: An immunocompetent patient diagnosed with PC was admitted in 2020. He had no history of immune deficiency but reported being extremely tired at the time and possibly exposed to pigeon dropping. The diagnosis was confirmed through serum cryptococcal antigen (CrAg) testing and pulmonary high-resolution computed tomography (HRCT) imaging, and the patient received oral fluconazole therapy immediately. During the treatment period, the serum was serially diluted to monitor CrAg changes via simple colloidal gold test strip detection to assess disease progression and therapeutic efficacy. After 4 months of oral fluconazole therapy, the serum CrAg was changed to negative, and the drug was discontinued after one month of maintenance therapy. Four years of follow-up revealed that the patient had recovered.
conclusionThis case proposes a simple and convenient method for the diagnosis and management of PC, particularly the use of serial dilutions of serum to track CrAg for the possibility of monitoring the efficacy of therapy and treatment duration. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.